Altimmune stock: 48-week pemvidutide MASH data, FDA Breakthrough Therapy boost, but rising competition and cash needs. Click ...

Roche remains a Buy, driven by strong pipeline progress and conservative valuation, with shares up 36% since my last recommendation. Learn more about RHHBY stock here.

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Results for 8-week 48 mg Cohort in Phase 1b Trial of DA-1726 ...

Despite receiving devices, education, and support, only one-third regularly took morning and night BP measurements as ...

Low-sodium oxybate reduces 24-hour sleep duration and daytime napping in adults with idiopathic hypersomnia, according to a phase 3 trial analysis.

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...

The global market for synthetic chemicals is witnessing a strategic realignment, driven by shifting supply chains, heightened ...

Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for ...

Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...

Detailed price information for Alaska Silver Corp (WAM-X) from The Globe and Mail including charting and trades.

Topline data expected in 1Q 2028Phase 2bipolar depression trial initiation follows positive Phase 2 results in acute schizophreniaNEW YORK, Jan.

Learn how medication errors lead to clinical negligence claims, from prescription failures to administration mistakes and ...